SCHEMBL4159422

SCHEMBL4159422

Cc1cc(Nc2nccc(-c3cccn3C)n2)ccc1S(=O)(=O)Nc1ncccn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 13/20 0.42
JAK2 O60674 5/20 0.42
JAK3 P52333 4/20 0.42
CDK4 P11802 6/20 0.41
CCNT1 O60563 2/20 0.41
CDK9 P50750 2/20 0.41
CDK1 P06493 2/20 0.41
CCNB1 P14635 1/20 0.41
CSNK2A2 P19784 1/20 0.41
CCNA2 P20248 1/20 0.41
CCND1 P24385 1/20 0.41
CCNE1 P24864 1/20 0.41
CCND3 P30281 1/20 0.41
MAPK8 P45983 1/20 0.41
MAPK9 P45984 1/20 0.41
CSNK1A1 P48729 1/20 0.41
CSNK1D P48730 1/20 0.41
GSK3A P49840 1/20 0.41
GSK3B P49841 1/20 0.41
CDK7 P50613 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4151825 0.81 ABL1 (0.52) CDK2JAK2JAK3CDK1MAPK8
SCHEMBL4138329 0.81 ABL1 (0.60) JAK3
SCHEMBL4154532 0.79 SYK (0.60) CDK2SYK
SCHEMBL4150544 0.79 SYK (0.46) CDK2JAK2JAK3CCNT1CDK9
SCHEMBL4146823 0.78 IKBKB (0.57) CDK2JAK2JAK3CDK1
SCHEMBL3517353 0.77 CDK2 (0.52) CDK2CDK4CCNT1CDK9CDK1
SCHEMBL3518870 0.76 ALDH1A1 (0.51) CDK2CDK4CCNT1CDK9CDK1
SCHEMBL7474055 0.76 PIK3CA (0.59) CDK2JAK2JAK3CDK1CCNB1
SCHEMBL3520839 0.74 CDK2 (0.52) CDK2CDK4CCNT1CDK9CDK1
SCHEMBL7465864 0.74 CDK2 (0.43) CDK2JAK2JAK3CDK4CCNE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090048282-A1 PYRIMIDINE SULFONAMIDE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM WYETH (US) 2009-02-19 US claimed
US-20090048282-A1 PYRIMIDINE SULFONAMIDE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM WYETH (US) 2009-02-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048282-A1 PYRIMIDINE SULFONAMIDE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM WNT1, CTNNB1, WNT3A CDK2 116/4885JAK2 904/4885JAK3 939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.